Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-NeoB + capecitabine in GRPR-positive ER-positive HER2-negative metastatic breast cancer
ISRCTN15516131Phase 2Terminated
- Sponsor
- Novartis
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of AAA503 and capecitabine in breast cancer, sponsored by Novartis. Primary endpoints: Safety and dose-limiting toxicities, Tolerability and 2 more. Started Sep 2024; status: terminated.
02
Drugs
AAA503capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN15516131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15516131.